First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer

Sponsor
Wales Cancer Trials Unit
Study ID
NCT01097317
Phase
PHASE2
Status
Unknown

Conditions

  • Chemotherapeutic Agent Toxicity
  • Fatigue
  • Lung Cancer
  • Musculoskeletal Complications

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • carboplatin — DRUG
  • vinorelbine tartrate — DRUG
  • neuromuscular electrical stimulation — OTHER
  • physiologic testing — OTHER
  • fatigue assessment and management — PROCEDURE
  • quality-of-life assessment — PROCEDURE

Study Details

RATIONALE: Drugs used in chemotherapy, such as carboplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemotherapy can lead to a loss of leg muscle strength. Neuromuscular electrical stimulation may improve muscle strength and quality of life. It is not yet known whether chemotherapy given together with neuromuscular electrical stimulation is more effective than chemotherapy alone in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying first-line chemotherapy given together with neuromuscular electrical stimulation to see how well it works compared with chemotherapy alone in treating patients with non-small cell lung cancer.

Key Dates

Start date
Sep 30, 2009
Status verified
Sep 2010
Primary completion
Sep 30, 2011

Study Design

Enrollment
52 participants (estimated)
Allocation
RANDOMIZED
Primary purpose
SUPPORTIVE_CARE

Primary Outcome Measure

Adherence to neuromuscular electrical stimulation (NMES) therapy

Related Studies